NOVELLO, Silvia
 Distribuzione geografica
Continente #
NA - Nord America 28.025
AS - Asia 20.269
EU - Europa 19.785
SA - Sud America 875
OC - Oceania 685
AF - Africa 358
Continente sconosciuto - Info sul continente non disponibili 240
Totale 70.237
Nazione #
US - Stati Uniti d'America 26.787
CN - Cina 9.441
IT - Italia 4.566
JP - Giappone 2.618
GB - Regno Unito 2.598
DE - Germania 1.904
SG - Singapore 1.886
IE - Irlanda 1.662
FR - Francia 1.600
IN - India 1.382
SE - Svezia 1.076
ES - Italia 1.055
KR - Corea 1.041
CA - Canada 1.004
HK - Hong Kong 767
VN - Vietnam 714
NL - Olanda 678
PL - Polonia 674
FI - Finlandia 602
AU - Australia 599
UA - Ucraina 552
TW - Taiwan 520
CH - Svizzera 465
BR - Brasile 463
TR - Turchia 444
AT - Austria 434
BE - Belgio 345
ID - Indonesia 345
IL - Israele 233
RU - Federazione Russa 224
DK - Danimarca 210
PT - Portogallo 197
TH - Thailandia 193
GR - Grecia 184
MX - Messico 176
RO - Romania 142
AP - ???statistics.table.value.countryCode.AP??? 129
IR - Iran 127
MY - Malesia 114
CZ - Repubblica Ceca 108
NO - Norvegia 108
AR - Argentina 106
EU - Europa 96
ZA - Sudafrica 96
PE - Perù 95
CO - Colombia 93
NZ - Nuova Zelanda 85
HU - Ungheria 84
PH - Filippine 74
EG - Egitto 70
CL - Cile 65
SA - Arabia Saudita 64
PK - Pakistan 63
JO - Giordania 53
RS - Serbia 50
MA - Marocco 40
HR - Croazia 34
SI - Slovenia 33
BG - Bulgaria 32
LT - Lituania 30
NG - Nigeria 28
MK - Macedonia 26
SK - Slovacchia (Repubblica Slovacca) 26
EC - Ecuador 24
BD - Bangladesh 20
CY - Cipro 20
DZ - Algeria 20
IQ - Iraq 19
LB - Libano 18
MO - Macao, regione amministrativa speciale della Cina 18
BY - Bielorussia 16
TN - Tunisia 16
UY - Uruguay 15
AE - Emirati Arabi Uniti 14
BA - Bosnia-Erzegovina 14
ET - Etiopia 14
AM - Armenia 13
LV - Lettonia 13
SN - Senegal 13
CR - Costa Rica 12
DO - Repubblica Dominicana 12
CU - Cuba 11
GH - Ghana 11
MT - Malta 11
UZ - Uzbekistan 11
KZ - Kazakistan 10
LY - Libia 10
UG - Uganda 10
VE - Venezuela 10
EE - Estonia 9
LK - Sri Lanka 9
XK - ???statistics.table.value.countryCode.XK??? 8
PA - Panama 7
TJ - Tagikistan 7
GT - Guatemala 6
LU - Lussemburgo 5
SC - Seychelles 5
AL - Albania 4
BO - Bolivia 4
GE - Georgia 4
Totale 70.153
Città #
Beijing 2.199
Dublin 1.615
Chandler 1.583
Santa Clara 1.518
Fairfield 1.444
Singapore 1.434
Houston 1.342
Redwood City 1.139
Shanghai 1.062
Woodbridge 856
Torino 848
Ashburn 833
Wilmington 779
Tokyo 667
Duncan 660
Ann Arbor 655
Seattle 630
Cambridge 539
Princeton 527
Guangzhou 523
Turin 481
Columbus 473
Medford 465
New York 432
Pisa 427
London 401
Hangzhou 396
Nanjing 392
Villeurbanne 354
Warsaw 353
Vienna 344
Jacksonville 343
Taipei 343
Nyköping 342
Dong Ket 297
Chengdu 283
Jakarta 280
Milan 258
Boston 255
Dearborn 245
Fremont 245
Jinan 241
Seoul 217
Madrid 211
Zhengzhou 206
Amsterdam 193
Toronto 191
Los Angeles 190
San Diego 180
Wuhan 179
Sydney 163
Paris 159
Changsha 155
Chicago 154
Rome 144
Mumbai 143
Central 140
Ottawa 133
Hong Kong 128
Munich 125
Barcelona 124
Philadelphia 124
Tianjin 117
Brussels 116
Central District 114
Shenyang 114
Boardman 112
Nutley 108
Hefei 107
Hyderabad 106
Manchester 105
Frankfurt am Main 101
Osaka 101
Düsseldorf 100
Hebei 100
Helsinki 98
São Paulo 98
Chongqing 97
Hanoi 96
Berlin 94
Zurich 94
Jerusalem 93
San Jose 91
Fuzhou 90
Atlanta 87
Bengaluru 85
Norwalk 84
Delhi 80
San Francisco 80
Chennai 78
Kunming 73
Bangkok 72
Xian 72
Pune 71
Collegeville 69
Nanchang 69
Newbury Park 69
Lima 68
Vancouver 68
Ho Chi Minh City 67
Totale 35.206
Nome #
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer 10.384
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer 4.851
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. 3.915
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. 3.628
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2.108
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study 1.666
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer 1.633
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s 1.306
Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer 840
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial 822
PARP inhibitors: an interesting pathway also for non-small cell lung cancer? 741
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial 659
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis 622
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer 553
Extending survival of stage IV non-small cell lung cancer. 533
Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled lume-meso trial 485
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 472
Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer? 451
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 446
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry 438
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. 416
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial 385
Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: A prospective study 383
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario 376
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Results from a multicenter Italian observational study 370
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma non-small cell lung cancer. 327
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study 326
Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer 323
Detection of EGFR mutations in archival lung cancer samples by pyrosequencing 318
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations 309
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 306
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. 305
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. 297
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 294
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 271
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 270
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report 268
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma 267
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. 262
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. 254
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. 248
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 241
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker 232
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 231
Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study 225
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. 216
ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. 202
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018 193
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. 189
Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 187
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 185
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin 175
Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. 172
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer 171
Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. 168
Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 168
Epidermal growth factor receptor tyrosine kinase inhibitors as adjuvant therapy in completely resected non-small-cell lung cancer 163
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer 154
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers 151
Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer 149
Fatigue in lung cancer patients: symptom burden and management of challenges. 146
Fetal adenocarcinoma of the lung in a 25-year-old woman 144
Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. 143
Clinical and biological significance of CD157 in malignant pleural mesothelioma 140
Current state-of-the-art therapy for advanced squamous cell lung cancer 140
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer 140
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 138
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. 138
Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib. 134
Thymidylate synthase expression in large cell carcinoma ofthe lung 133
Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer 133
Clonal Heterogeneity in Non-Small Cell Lung Cancer and the Possible Role in Predicting Response to Treatment with Immune Checkpoint Inhibitors 133
Tackling ALK in non-small cell lung cancer: The role of novel inhibitors 132
Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era 130
Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey 129
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer 128
Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield 126
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients 126
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study 126
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 126
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung 121
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma 120
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases 119
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 118
First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era 118
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. 118
Diagnostica per immagini 117
Trattamento del carcinoma polmonare in stadio avanzato. Dall’approccio classico alla medicina di precisione e prospettive future. 116
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine 116
IκBα targeting promotes oxidative stress-dependent cell death 116
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 116
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion 115
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival 115
SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer 114
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 114
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study 112
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer: A Phase-II Study. 112
Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread? 112
Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study 108
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial 108
Totale 51.690
Categoria #
all - tutte 155.492
article - articoli 0
book - libri 0
conference - conferenze 5.352
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.844


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.691 0 0 0 0 0 1.023 978 801 884 721 698 586
2020/202111.991 583 623 911 960 1.156 1.079 901 947 1.144 1.151 979 1.557
2021/202211.605 946 892 901 959 882 780 996 895 836 830 1.364 1.324
2022/202310.785 930 788 522 923 878 1.925 895 893 1.075 520 766 670
2023/20249.372 996 1.090 713 786 733 773 869 884 181 742 741 864
2024/20257.158 544 1.132 832 1.304 2.462 884 0 0 0 0 0 0
Totale 72.464